Pgiam/iStock via Getty Images
Leerink Partners downgraded Johnson & Johnson (NYSE:JNJ) and Halozyme Therapeutics (NASDAQ:HALO) on Tuesday, indicating a faster-than-expected timeline for the companies’ combination drug products to face Medicare price negotiations.
Halozyme (NASDAQ:HALO) was downgraded to Underperform from Market Perform, while J&J (